ticlopidine has been researched along with Gastroduodenal Ulcer in 43 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients with atherosclerosis and a history of peptic ulcers, the combination of esomeprazole and clopidogrel reduced recurrence of peptic ulcers, compared with clopidogrel alone." | 9.15 | Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. ( Hsu, PI; Lai, KH; Liu, CP, 2011) |
| " As a result, clopidogrel's incidence of peptic ulcer disease (PUD) and ulcer bleeding is lower than aspirin's." | 9.15 | Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. ( Chen, LC; Hou, MC; Huang, KW; Lee, FY; Lee, SD; Leu, HB; Li, CP; Lin, HC; Lu, CL; Luo, JC, 2011) |
| "In patients with aspirin-associated peptic ulcer disease of low to moderate grade, both early conversion from aspirin to clopidogrel and continuation of aspirin are safe." | 9.11 | Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study. ( Chang, CM; Chen, WH; Ng, FH; Wong, BC; Wong, SY, 2004) |
| "This survey depicts individual discrepancies in the clinical management of patients receiving NSAIDs and/or aspirin, regarding the prophylaxis of gastroduodenal ulcer disease." | 7.78 | [Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori]. ( Armbruster, S; Mann, J; Schepp, W; Schneider, AR; Schuster, T; von Römer, W, 2012) |
| "This multicenter retrospective study investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel (A + C) cotherapy." | 7.74 | Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. ( Chan, P; Cheung, TK; Kng, C; Kwanching, CP; Lai, ST; Loo, CK; Ng, FH; Ng, KM; Wong, BC; Wong, SY, 2008) |
| "To evaluate the safety of clopidogrel in patients with peptic ulcer disease in a retrospective cohort longitudinal study." | 7.72 | High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003) |
| "From January 2012 to 2016, long-termed thienopyridine users with a peptic ulcer history who did not have peptic ulcers at initial endoscopy were randomly assigned to receive either famotidine (40 mg, before bedtime) or placebo (before bedtime) for 6 months." | 5.24 | Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. ( Chen, WC; Cheng, JS; Hsu, PI; Kao, SS; Lai, KH; Liu, CP; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC, 2017) |
| " Patients with Helicobacter pylori infection and a history of peptic ulcer were assigned dual antiplatelet combination with omeprazole." | 5.17 | Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting. ( Chen, G; Du, Y; Hang, L; Ma, B, 2013) |
| "Among patients with atherosclerosis and a history of peptic ulcers, the combination of esomeprazole and clopidogrel reduced recurrence of peptic ulcers, compared with clopidogrel alone." | 5.15 | Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. ( Hsu, PI; Lai, KH; Liu, CP, 2011) |
| " As a result, clopidogrel's incidence of peptic ulcer disease (PUD) and ulcer bleeding is lower than aspirin's." | 5.15 | Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. ( Chen, LC; Hou, MC; Huang, KW; Lee, FY; Lee, SD; Leu, HB; Li, CP; Lin, HC; Lu, CL; Luo, JC, 2011) |
| "In patients with aspirin-associated peptic ulcer disease of low to moderate grade, both early conversion from aspirin to clopidogrel and continuation of aspirin are safe." | 5.11 | Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study. ( Chang, CM; Chen, WH; Ng, FH; Wong, BC; Wong, SY, 2004) |
| "Long-term use of aspirin and severity of cerebral infarction are risk factors for gastrointestinal bleeding in cerebral infarction patients receiving dual antiplatelet therapy." | 4.31 | Risk factors for gastrointestinal bleeding in patients with cerebral infarction after dual antiplatelet therapy. ( Huang, J; Liao, F; Shu, X; Tang, J, 2023) |
| " Cox proportional hazard regression models were developed to evaluate the predictors of LGIB with adjustments for age, gender, comorbidities including coronary artery disease, ischaemic stroke, diabetes, hypertension, chronic kidney disease, liver cirrhosis, chronic obstructive pulmonary disease, dyslipidemia, uncomplicated peptic ulcer disease, history of peptic ulcer bleeding, and concomitant use of clopidogrel, ticlopidine, warfarin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, steroids, proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), nitrates, alendronate, selective serotonin reuptake inhibitors (SSRIs) and calcium channel blockers." | 3.85 | The risk of lower gastrointestinal bleeding in low-dose aspirin users. ( Chen, WC; Chuah, SK; Hsu, PI; Huang, YT; Lin, KH; Sun, WC; Tsai, TJ; Wu, DC, 2017) |
| "Increased incidence of coronary artery disease has led to the increased use of dual antiplatelet therapy composed of aspirin and clopidogrel." | 3.80 | [Clinical impact of dual antiplatelet therapy on peptic ulcer disease]. ( Ahn, DG; Kim, BJ; Kim, JG; Kim, JW, 2014) |
| "Low-dose aspirin (ASA) has emerged as one of the most important causes of peptic ulcer bleeding in developed countries." | 3.78 | Anti-platelet therapy and managing ulcer risk. ( Chan, FK, 2012) |
| " In the management of aspirin-related uncomplicated peptic ulcers in patients requiring antiplatelet therapies, continuing aspirin plus a powerful proton pump inhibitor is the choice of treatment." | 3.78 | New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. ( Hsu, PI, 2012) |
| "This survey depicts individual discrepancies in the clinical management of patients receiving NSAIDs and/or aspirin, regarding the prophylaxis of gastroduodenal ulcer disease." | 3.78 | [Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori]. ( Armbruster, S; Mann, J; Schepp, W; Schneider, AR; Schuster, T; von Römer, W, 2012) |
| "The frequencies of hemorrhagic spots, erosions and peptic ulcers in the symptomatic clopidogrel users were 25%, 39% and 39%, respectively." | 3.78 | Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. ( Chan, HH; Chang, SN; Hsiao, SH; Hsu, PI; Huang, HR; Lai, KH; Lin, CH; Lin, CK; Lin, KH; Liu, CP; Tsai, TJ; Tsay, FW; Wang, HM; Wang, KM; Yu, HC, 2012) |
| "This study was conducted to compare the risk of recurrent hospitalization for major gastrointestinal (GI) complications (peptic ulcer, bleeding, and perforation) in patients at high GI risk who require ongoing antiplatelet therapy (aspirin [acetylsalicylic acid] or clopidogrel) with or without proton pump inhibitors (PPIs)." | 3.75 | A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. ( Chang, PY; Chen, PF; Hsiao, FY; Huang, WF; Kuo, KN; Tsai, YW; Wen, YW, 2009) |
| "This multicenter retrospective study investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel (A + C) cotherapy." | 3.74 | Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. ( Chan, P; Cheung, TK; Kng, C; Kwanching, CP; Lai, ST; Loo, CK; Ng, FH; Ng, KM; Wong, BC; Wong, SY, 2008) |
| "To evaluate the safety of clopidogrel in patients with peptic ulcer disease in a retrospective cohort longitudinal study." | 3.72 | High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003) |
| "Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were divided into "low-dose" (≤ 100 mg) and "high-dose" (>100 mg) aspirin groups." | 2.82 | Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. ( Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M, 2016) |
| " The grade of gastric mucosal injuries was evaluated by esophagogastroduodenoscopy before and after dosing (on day 0 and day 14), and the grade of gastric mucosal injury was assessed according to the modified Lanza score." | 2.79 | A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. ( Fukui, H; Hida, N; Hori, K; Miwa, H; Nakamura, S; Ogawa, T; Ohda, Y; Okugawa, T; Oshima, T; Tomita, T; Tozawa, K; Watari, J, 2014) |
| "Many individuals with gastroduodenal ulcers require on-going, non-steroidal anti-inflammatory drug (NSAID) or anti-platelet therapy." | 2.74 | A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing. ( Aisenberg, J; Bamji, N; Bodian, C; Brooks, A; Cohen, L; Desai, J; Dikman, A; Miller, K; Sanyal, S; VON Althann, C; Whitson, M, 2009) |
| "Regardless of dose, adjusted odds ratios associating clopidogrel use with the study endpoint were statistically significant and followed a dose-response pattern." | 1.39 | Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. ( Grove, EL; Jørgensen, NR; Schwarz, P; Vestergaard, P; Würtz, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (20.93) | 29.6817 |
| 2010's | 33 (76.74) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J | 1 |
| Liao, F | 1 |
| Tang, J | 1 |
| Shu, X | 1 |
| Chen, WC | 2 |
| Lin, KH | 2 |
| Huang, YT | 1 |
| Tsai, TJ | 3 |
| Sun, WC | 1 |
| Chuah, SK | 1 |
| Wu, DC | 2 |
| Hsu, PI | 5 |
| Amagase, K | 1 |
| Yoshida, Y | 1 |
| Hara, D | 1 |
| Murakami, T | 1 |
| Takeuchi, K | 1 |
| Jiang, Z | 1 |
| Wu, H | 1 |
| Duan, Z | 1 |
| Wang, Z | 1 |
| Hu, K | 1 |
| Ye, F | 1 |
| Zhang, Z | 1 |
| Ma, B | 1 |
| Hang, L | 1 |
| Chen, G | 1 |
| Du, Y | 1 |
| Tozawa, K | 1 |
| Oshima, T | 1 |
| Okugawa, T | 1 |
| Ogawa, T | 1 |
| Ohda, Y | 1 |
| Tomita, T | 1 |
| Hida, N | 1 |
| Fukui, H | 1 |
| Hori, K | 1 |
| Watari, J | 1 |
| Nakamura, S | 1 |
| Miwa, H | 1 |
| Wang, Q | 1 |
| Ljung, R | 1 |
| Lagergren, J | 1 |
| Lu, Y | 1 |
| Ahn, DG | 1 |
| Kim, BJ | 1 |
| Kim, JW | 1 |
| Kim, JG | 1 |
| Kim, JJ | 1 |
| Kim, N | 1 |
| Vaduganathan, M | 1 |
| Bhatt, DL | 1 |
| Cryer, BL | 1 |
| Liu, Y | 1 |
| Hsieh, WH | 1 |
| Doros, G | 1 |
| Cohen, M | 1 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 2 |
| Cannon, CP | 1 |
| Zhang, ZF | 1 |
| Sha, WH | 1 |
| Tan, GY | 1 |
| Wang, QY | 1 |
| Würtz, M | 2 |
| Grove, EL | 2 |
| Tsay, FW | 2 |
| Cheng, JS | 1 |
| Liu, CP | 3 |
| Lai, KH | 3 |
| Wang, HM | 2 |
| Tsai, KW | 1 |
| Kao, SS | 1 |
| Ng, FH | 3 |
| Chan, P | 1 |
| Kwanching, CP | 1 |
| Loo, CK | 1 |
| Cheung, TK | 1 |
| Wong, SY | 3 |
| Kng, C | 2 |
| Ng, KM | 1 |
| Lai, ST | 1 |
| Wong, BC | 3 |
| Dikman, A | 1 |
| Sanyal, S | 1 |
| VON Althann, C | 1 |
| Whitson, M | 1 |
| Desai, J | 1 |
| Bodian, C | 1 |
| Brooks, A | 1 |
| Bamji, N | 1 |
| Cohen, L | 1 |
| Miller, K | 1 |
| Aisenberg, J | 1 |
| Cryer, B | 1 |
| Luo, JC | 2 |
| Doherty, GA | 1 |
| Cannon, MD | 1 |
| Lynch, KM | 1 |
| Ayoubi, KZ | 1 |
| Harewood, GC | 1 |
| Patchett, SE | 1 |
| Murray, FE | 1 |
| Hsiao, FY | 2 |
| Tsai, YW | 2 |
| Huang, WF | 2 |
| Wen, YW | 2 |
| Chen, PF | 2 |
| Chang, PY | 1 |
| Kuo, KN | 2 |
| Mourad, JJ | 1 |
| Marcucci, R | 1 |
| Madanick, RD | 1 |
| Hiraishi, H | 1 |
| Maeda, M | 1 |
| Sasai, T | 1 |
| Kanke, K | 1 |
| Shimada, T | 1 |
| Bae, SE | 1 |
| Kim, SE | 1 |
| Jung, SA | 1 |
| Yoon, SY | 1 |
| Shim, KN | 1 |
| Jung, HK | 1 |
| Kim, TH | 1 |
| Yoo, K | 1 |
| Moon, IH | 1 |
| Huang, KW | 1 |
| Leu, HB | 1 |
| Chen, LC | 1 |
| Hou, MC | 1 |
| Li, CP | 1 |
| Lu, CL | 1 |
| Lin, HC | 1 |
| Lee, FY | 1 |
| Lee, SD | 1 |
| Labos, C | 1 |
| Dasgupta, K | 1 |
| Nedjar, H | 1 |
| Turecki, G | 1 |
| Rahme, E | 1 |
| Messinger-Rapport, BJ | 1 |
| Morley, JE | 1 |
| Thomas, DR | 1 |
| Gammack, JK | 1 |
| Almadi, MA | 1 |
| Barkun, A | 1 |
| Brophy, J | 1 |
| Chan, FK | 1 |
| Struijk, M | 1 |
| Postma, DF | 1 |
| van Tuyl, SA | 1 |
| van de Ree, MA | 1 |
| Häuptle, R | 1 |
| Weilenmann, D | 1 |
| Schneider, T | 1 |
| Haile, SR | 1 |
| Ammann, P | 1 |
| Knellwolf, C | 1 |
| Borovicka, J | 1 |
| Uotani, T | 1 |
| Sugimoto, M | 1 |
| Nishino, M | 1 |
| Kodaira, C | 1 |
| Yamade, M | 1 |
| Sahara, S | 1 |
| Yamada, T | 1 |
| Osawa, S | 1 |
| Sugimoto, K | 1 |
| Tanaka, T | 1 |
| Umemura, K | 1 |
| Watanabe, H | 1 |
| Miyajima, H | 1 |
| Furuta, T | 1 |
| Schwarz, P | 1 |
| Jørgensen, NR | 1 |
| Vestergaard, P | 1 |
| Schneider, AR | 1 |
| Armbruster, S | 1 |
| Mann, J | 1 |
| von Römer, W | 1 |
| Schuster, T | 1 |
| Schepp, W | 1 |
| Lin, CK | 1 |
| Chan, HH | 1 |
| Yu, HC | 1 |
| Wang, KM | 1 |
| Chang, SN | 1 |
| Hsiao, SH | 1 |
| Huang, HR | 1 |
| Lin, CH | 1 |
| Chang, CM | 2 |
| Chen, WH | 2 |
| Lanas, AI | 1 |
| Ziegelin, M | 1 |
| Hoschtitzky, A | 1 |
| Dunning, J | 1 |
| Hooper, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer and Gastrointestinal Bleeding[NCT01138969] | Phase 2 | 165 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Institute of Emergency and Critical Care Medicine , School of Yang-Ming University[NCT01588886] | 9,000 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| Comparison of Ulcer Healing in Patients Taking Rabeprazole Plus Aspirin Versus Rabeprazole Plus Clopidogrel for Acute Peptic Ulcer[NCT01037491] | 200 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
participants with peptic ulcer bleeding within 6 months (NCT01138969)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Plus Clopidogrel Group | 0 |
| Clopidogrel Group | 1 |
Number of participants with recurrent peptic ulcer within 6 months (NCT01138969)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Plus Clopidogrel Group | 1 |
| Clopidogrel Group | 9 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
7 reviews available for ticlopidine and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Dosage | 2017 |
PPI interactions with clopidogrel.
Topics: Anti-Ulcer Agents; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Gastroesophageal Reflux; | 2009 |
Management of patients with high gastrointestinal risk on antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Peptic Ulcer Hemorrhage; Pi | 2009 |
Proton pump inhibitor side effects and drug interactions: much ado about nothing?
Topics: Anemia, Iron-Deficiency; Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Fractures, Spontaneous; | 2011 |
[Strategy to manage low dose aspirin-induced gastrointestinal injury].
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Famotid | 2011 |
Optimal drug therapy after aspirin-induced upper gastrointestinal bleeding.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Pl | 2012 |
Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery?
Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicin | 2007 |
9 trials available for ticlopidine and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting.
Topics: Angiography; Aspirin; Breath Tests; Carotid Arteries; Carotid Stenosis; Clopidogrel; Drug Interactio | 2013 |
A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel.
Topics: Adult; Alanine; Anti-Ulcer Agents; Aspirin; Clopidogrel; Double-Blind Method; Gastric Mucosa; Gastro | 2014 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; | 2016 |
Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atherosclerosis; Clopidogrel; Double-Blind Method; F | 2017 |
A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clopidogrel; Drug Administ | 2009 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Clopid | 2011 |
Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; As | 2012 |
Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk -- a single-blind, randomized controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aspirin; Clopidogrel; Female; Humans; | 2004 |
27 other studies available for ticlopidine and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Risk factors for gastrointestinal bleeding in patients with cerebral infarction after dual antiplatelet therapy.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; H | 2023 |
The risk of lower gastrointestinal bleeding in low-dose aspirin users.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2017 |
Prophylactic effect of egualen sodium, a stable azulene derivative, on gastrointestinal damage induced by ischemia/reperfusion, double antiplatelet therapy and loxoprofen in rats.
Topics: Animals; Aspirin; Azulenes; Benzoquinones; Clopidogrel; Gastric Mucosa; Gastrointestinal Hemorrhage; | 2013 |
Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Alcohol Drinking; Angina, Stable; Aspirin; Case-Control | 2013 |
Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Interactions; Fe | 2014 |
[Clinical impact of dual antiplatelet therapy on peptic ulcer disease].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Angiography; Coronary | 2014 |
[Does dual antiplatelet therapy increase the risk of peptic ulcer disease?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Huma | 2014 |
[The incidence, clinical characteristics and risk factors of upper gastrointestinal bleeding in patients taking dual antiplatelet therapy after percutaneous coronary intervention in south China].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Coronary Artery Disease; Femal | 2016 |
Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Disease; Female; Gastr | 2008 |
Gastroprotective strategy in aspirin users.
Topics: Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Hum | 2009 |
Co-prescription of gastro-protectants in hospitalized patients: an analysis of what we do and what we think we do.
Topics: Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Clopidogrel; Data Collection; Female | 2010 |
A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Databases, Factual; Drug Cos | 2009 |
Withdrawal of clopidogrel in active gastric bleeding.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Gastrointestinal Hemorrhag | 2010 |
Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Dru | 2011 |
[Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Elect | 2010 |
Proton pump inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm?
Topics: Atherosclerosis; Clopidogrel; Drug Interactions; Humans; Omeprazole; Peptic Ulcer; Platelet Aggregat | 2011 |
[The effect of aspirin alone or aspirin plus additional antiplatelets therapy on upper gastrointestinal hemorrhage].
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
Clinical update on nursing home medicine: 2011.
Topics: Anti-Ulcer Agents; Anticoagulants; Atrial Fibrillation; Clopidogrel; Clostridioides difficile; Delir | 2011 |
Antiplatelet and anticoagulant therapy in patients with gastrointestinal bleeding: an 86-year-old woman with peptic ulcer disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Interaction | 2011 |
Anti-platelet therapy and managing ulcer risk.
Topics: Animals; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Combined Modali | 2012 |
New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Helic | 2012 |
Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Adverse Drug Reaction Reporting Systems; Aged; Ang | 2012 |
Gastrointestinal events with clopidogrel: a nationwide population-based cohort study.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Denmark; Dose-Response Relationship, Dru | 2013 |
[Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori].
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Clopid | 2012 |
Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Endoscopy, Gastrointestinal; Female; Gastrointestinal | 2012 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |